MedTrace Logo

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

NCT00555594 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-08-01

No results posted yet for this study

Summary

To determine the effect of subconjunctival Bevacizumab in corneal neovascularization

Conditions

  • Corneal Neovascularization

Interventions

DRUG

Bevacizumab (Avastin)

One dose of 0.1cc of subconjunctival Bevacizumab was applied

Sponsors & Collaborators

  • National Council of Science and Technology, Mexico

    collaborator OTHER

  • Universidad Nacional Autonoma de Mexico

    collaborator OTHER

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Hernández-Quintela Everardo, MD · Consejo Nacional de Ciencia y Tecnología (CONACYT) grant no. 115755 (EHQ)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2006-09-30
Completion
2007-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555594 on ClinicalTrials.gov